Clinical Trial Update: An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients

View source ↗

Summary

An observational study assessing the impact of the 23-valent pneumococcal vaccine on patients with lung cancer. The study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Pneumococcal polysaccharide vaccine, 23-valent (PPSV23) (PPSV23)

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: LUNG CANCER | Status: NOT_YET_RECRUITING